Advertisement
A comprehensive program of research will be presented in ERS symposiumsand poster sessions relating to the lung challenge product, Aridol, and themucus clearing agent, Bronchitol.
Advertisement
In a poster session Professor Di Bilton, Consultant Physician and HonorarySenior Lecturer at the Department of Respiratory Medicine, The Royal BromptonHospital, London, UK, will detail results of a successful randomized, placebo-controlled trial of inhaled mannitol (Bronchitol) in patients withbronchiectasis.
Other key ERS program events from the Pharmaxis respiratory diseaseprogram include:
ERS is Europe's biggest annual scientific gathering in respiratorymedicine, with more than 17,000 participants each year. It aims to provide aplatform for important improvements in the treatment of lung diseases. Fulldetails of ERS may be viewed on the ERS website athttp://dev.ersnet.org/415-general-information.htm
Forward-Looking Statements
The statements contained in this media release that are not purelyhistorical are forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended. Forward-looking statements inthis media release include statements regarding our expectations, beliefs,hopes, goals, intentions, initiatives or strategies, including statementsregarding the potential for Aridol and/or Bronchitol. All forward-lookingstatements included in this media release are based upon information availableto us as of the date hereof, and we assume no obligation to update any suchforward-looking statement as a result of new information, future events orotherwise. We can not guarantee that any product candidate will receive FDA orother regulatory approval or that we will seek any such approval. Factors thatcould cause or contribute to such differences include, but are not limited to,factors discussed in the "Risk Factors and Other Uncertainties" section of ourForm 20-F lodged with the U.S. Securities and Exchange Commission.-- The use of inhaled mannitol (Aridol) for assessing airway disease -- Direct versus indirect airway challenges -- Using a dry powder of mannitol (Aridol) versus methacholine as challenge for routine practice -- Inhaled mannitol (Bronchitol) as treatment for children with cystic fibrosis -- Implications for everyday practice -- Infectious lung diseases including tuberculosis -- A randomized, placebo-controlled trial of inhaled mannitol(Bronchitol) in patients with bronchiectasis -- Cough and airway hyperresponsiveness -- A comparison of inhaled mannitol (Aridol), methacholine provocation and eucapnic voluntary hyperventilation as diagnostic tests for exercised-induced bronchoconstriction in cross country skiers -- Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children -- Mannitol dry powder challenge (Aridol) in comparison with exercise testing and methacholine challenge test in children -- Responsiveness to mannitol (Aridol) and exercise challenge in children with asthma -- Association between mannitol dry powder challenge (Aridol) test results and fractional exhaled nitric oxide in children -- Exercise-induced asthma, acute severe asthma and allergic rhinitis in children -- Change of exercise challenge tests and mannitol challenge test (Aridol) during optimized asthma treatment in adolescents with exercise induced asthma -- Investigation, inspiration, ventilation, dedication: the essence of physiological measurement -- The perception of breathlessness during bronchoconstriction induced by mannitol (Aridol) in COPD -- Phenotyping of asthma and COPD -- Airway hyperresponsiveness to mannitol (Aridol) and exhaled NO are related to inflammatory subtypes in asthma.
SOURCE Pharmaxis
